RecruitingNCT03276923

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

Sponsor

Duke University

Enrollment

1,000 participants

Start Date

Jan 1, 2018

Study Type

OBSERVATIONAL

Conditions

Rheumatoid Arthritis Scleroderma Systemic Lupus Erythematosus Sjogren's Syndrome Pregnancy Related Autoimmune Diseases Cutaneous Lupus

Summary

This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.

Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This registry study is collecting health information from women with autoimmune diseases who are pregnant or trying to become pregnant, to better understand how these conditions and their treatments affect pregnancy outcomes. **You may be eligible if...** - You are a woman who wants to become pregnant within 6 months or is currently pregnant - You have an autoimmune disease such as lupus, antiphospholipid syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, inflammatory arthritis (including psoriatic arthritis or ankylosing spondylitis), vasculitis, myositis, or undifferentiated connective tissue disease **You may NOT be eligible if...** - You are unable to speak English - You are unable to provide informed consent - You are unable to travel to Duke University for follow-up visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.